Post Approval Study to Evaluate the Effectiveness and Safety of Cartiva Implant in the Treatment of OA of the Great Toe

Cartiva, Inc.135 enrolled

Overview

Evaluate and confirm the long-term safety and effectiveness of the Cartiva SCI implant established by the pivotal trial.

As part of the Conditions of Approval of Cartiva SCI for the treatment of first MTP osteoarthritis, the Food and Drug Administration (FDA) requires additional long term data to evaluate the long term safety and effectiveness of Cartiva including the durability and survivorship of the implant. This Post-Approval Study (PAS) addendum is intended to supplement the initial 24 months follow up period and provide additional long term safety and effectiveness data on Cartiva

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

135

Conditions

Osteoarthritis of First Metatarsalphalangeal Joint

Interventions

CartivaDEVICE

Cartiva Synthetic Cartilage Implant

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject must have been treated with Cartiva under MOTION study protocol PTC-0031; and, * Have been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the IRB/Ethics Committee for long-term follow-up. Exclusion Criteria: * Subjects who underwent a secondary surgical intervention to have the Cartiva implant removed during the 24-month time period of participation in the MOTION study.

Outcomes

Primary Outcomes

Long Term Safety of the Cartiva Implant by demonstrating durability over the long term and no unanticipated safety concerns that arise

1. Durability of the implant over the longer term. This will be addressed using survival analysis starting at Month 24 to determine the rate of implant removals among devices that survived to Month 24. A complementary survival analysis starting at index surgery to end of study will also be performed. 2. There are no unanticipated safety concerns that arise after Month 24 up to 5 years. This will be addressed by a) determining the incidence of serious device-related adverse events per year and overall from Month 24 to Year 5; and b) summarizing device-related radiographic complications1 over time from Month 24 to Year 5. Note that this analysis will address both device and procedure related complications and serious device-related adverse events whether observed previously in the 24 month follow up portion of the study or encountered for this first time during the extended follow-up period.

Time frame: 5 year

Secondary Outcomes

Pain Scale (VAS)

Visual Analog Scale (VAS) Pain

Time frame: 5 year

Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL)

Foot and Ankle Ability Measure (FAAM) Activities of Daily Living scores

Time frame: 5 year

Foot and Ankle Ability Measure (FAAM) Sports

Foot and Ankle Ability Measure (FAAM) Sports scores

Time frame: 5 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.